Corbus Pharmaceuticals Email Format

Pharmaceutical ManufacturingMassachusetts, United States51-200 Employees

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, focused on developing therapies for oncology and obesity. Operating in the pharmaceutical manufacturing landscape, it advances scientific approaches to biological pathways connected with cancer and weight management. Its pipeline includes CRB-701, a next-generation antibody-drug conjugate that targets Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks activation of TGFβ expressed on cancer cells; and CRB-913, a peripherally restricted CB1 receptor inverse agonist intended for obesity. The company aims to translate laboratory findings into clinical testing to address serious illnesses.

Recent 2026 developments include leadership and governance updates, such as the appointment of Nishant Saxena as Chief Business Officer and the addition of Brent Pfeiffenberger to the Board. It also engages with the clinical community through ASCO-related events to discuss updated data from its CRB-701 program. Corbus operates from Norwood and trades on the Nasdaq under the ticker CRBP.

Sign up for free to view info

Company overview Employee directory